GSA Capital Partners LLP Has $629,000 Position in AbCellera Biologics Inc. (NASDAQ:ABCL)

GSA Capital Partners LLP boosted its holdings in shares of AbCellera Biologics Inc. (NASDAQ:ABCL) by 991.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 241,866 shares of the company’s stock after acquiring an additional 219,703 shares during the quarter. GSA Capital Partners LLP owned approximately 0.08% of AbCellera Biologics worth $629,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Arcadia Investment Management Corp MI bought a new position in AbCellera Biologics during the third quarter valued at approximately $26,000. Evergreen Capital Management LLC bought a new position in AbCellera Biologics during the second quarter valued at approximately $32,000. NBC Securities Inc. raised its position in AbCellera Biologics by 56.0% during the third quarter. NBC Securities Inc. now owns 11,420 shares of the company’s stock valued at $29,000 after acquiring an additional 4,100 shares in the last quarter. Ballentine Partners LLC bought a new position in AbCellera Biologics during the third quarter valued at approximately $54,000. Finally, B. Riley Wealth Advisors Inc. raised its position in AbCellera Biologics by 104.8% during the second quarter. B. Riley Wealth Advisors Inc. now owns 21,500 shares of the company’s stock valued at $64,000 after acquiring an additional 11,000 shares in the last quarter. Institutional investors own 61.42% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ABCL. Stifel Nicolaus reaffirmed a “buy” rating and set a $12.00 price objective (down previously from $14.00) on shares of AbCellera Biologics in a research report on Tuesday, November 5th. Benchmark reissued a “hold” rating on shares of AbCellera Biologics in a research report on Tuesday, November 5th.

AbCellera Biologics Price Performance

NASDAQ:ABCL opened at $2.65 on Tuesday. AbCellera Biologics Inc. has a 12 month low of $2.34 and a 12 month high of $6.05. The firm has a market cap of $782.72 million, a price-to-earnings ratio of -4.34 and a beta of 0.35. The company’s 50 day moving average is $2.68 and its 200-day moving average is $2.98.

AbCellera Biologics (NASDAQ:ABCL) last announced its earnings results on Monday, November 4th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). AbCellera Biologics had a negative return on equity of 15.73% and a negative net margin of 533.32%. The company had revenue of $6.51 million for the quarter, compared to the consensus estimate of $8.95 million. During the same period last year, the firm posted ($0.10) EPS. Research analysts predict that AbCellera Biologics Inc. will post -0.59 EPS for the current fiscal year.

AbCellera Biologics Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.